Journal article
Ferric Carboxymaltose
Hospital pharmacy (Philadelphia), Vol.49(1), pp.52-59
01/2014
Handle:
https://hdl.handle.net/2376/106278
PMCID: PMC3887599
PMID: 24421564
Abstract
Each month, subscribers to
The Formulary Monograph Service
receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with
The Formulary Monograph Service.
Through the cooperation of
The Formulary, Hospital Pharmacy
publishes selected reviews in this column. For more information about
The Formulary Monograph Service,
call
The Formulary
at 800-322-4349. The January 2014 monograph topics are obinutuzumab, anti-inhibitor coagulant complex, macitentan, riociguat, and conjugated estrogens/bazedoxifene. The DUE/MUE is on conjugated estrogens/bazedoxifene.
Metrics
11 Record Views
Details
- Title
- Ferric Carboxymaltose
- Creators
- Dennis J Cada - Founder and Contributing EditorTerri L Levien - Clinical Associate Professor of Pharmacotherapy, Drug Information Center, Washington State University, Spokane, WashingtonDanial E Baker - Director, Drug Information Center, and Professor of Pharmacy Practice, College of Pharmacy, Washington State University Spokane, PO Box 1495, Spokane, Washington 99210-1495
- Publication Details
- Hospital pharmacy (Philadelphia), Vol.49(1), pp.52-59
- Academic Unit
- Pharmacotherapy, Department of
- Publisher
- Thomas Land Publishers, Inc
- Identifiers
- 99900547095301842
- Language
- English
- Resource Type
- Journal article